Analysis of Antiepileptic Drugs in Plasma for Clinical Research

Importance of the topic

Pharmacokinetic and pharmacodynamic interactions among antiepileptic drugs can significantly affect therapeutic outcomes. Accurate, high-throughput quantification of multiple antiepileptic compounds in plasma is essential for clinical research, drug development, and therapeutic drug monitoring.

Objectives and study overview

This study aimed to develop and validate a rapid, sensitive UPLC-MS/MS method for simultaneous determination of 18 antiepileptic drugs and metabolites in human plasma. The method employs protein precipitation sample preparation and a five-minute chromatographic run to support pharmacokinetic investigations.

Instrumentation used

• Waters ACQUITY UPLC I-Class with Flow-Through Needle (FTN)
• CORTECS C8 Column, 2.7 µm, 2.1 × 50 mm
• Waters Xevo TQD Triple Quadrupole Mass Spectrometer
• MassLynx Software v4.2 with TargetLynx Application Manager

Methodology

Protein precipitation was performed by adding 200 µL of methanol containing stable-labeled internal standards to 50 µL plasma, followed by vortexing and centrifugation. The supernatant was diluted and injected (20 µL). Chromatographic separation used a water/methanol gradient with 2 mM ammonium acetate at 0.5 mL/min, 50 °C, achieving separation in 5 minutes. MRM detection with positive/negative polarity switching provided specific transitions for each analyte.

Main results and discussion

• No system carryover was observed across high-concentration samples.
• Lower limits of quantification ranged from 0.0075 to 1.5 µg/mL, with precision ≤20% CV and bias ≤15%.
• Total precision at low, mid, and high QC levels showed CV ≤9.5%; repeatability CV ≤9.5%.
• Calibration was linear or quadratic over respective concentration ranges for all analytes.
• Matrix effects were minimal (matrix factors 0.9–1.02), compensated by internal standards.
• Endogenous interferences (e.g. lipids, bilirubin) had recoveries of 85–113%.
• External proficiency testing showed deviations ≤10.6% from assigned values.

Benefits and practical applications

The method uses low plasma volumes and simple preparation, enabling high sample throughput for pharmacokinetic studies. Simultaneous analysis of 18 drugs and metabolites facilitates comprehensive drug interaction research and therapeutic monitoring in clinical and research laboratories.

Future trends and opportunities

• Expansion to include emerging antiepileptic compounds and metabolites.
• Integration with high-resolution mass spectrometry for untargeted metabolomics.
• Miniaturization and automation of sample preparation (e.g. dried blood spots).
• Implementation of AI-driven data processing for real-time pharmacokinetic modeling.
• Integration with multi-omic platforms to study drug–biomarker interactions.

Conclusion

The validated UPLC-MS/MS method offers robust, precise, and sensitive quantification of 18 antiepileptic drugs and metabolites in plasma. Its high throughput, minimal matrix effects, and agreement with external quality schemes make it well suited for clinical research and therapeutic monitoring.

References

• Balloch S., Calton L., Hammond G. Analysis of Antiepileptic Drugs in Plasma for Clinical Research. Waters Corporation Application Note, March 2020.